Share this

KN-581 KSA

Back

References:

  1. J. Motzer et. al, 2024 Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study; June 2024 https://doi.org/10.1200/JCO.23.01569
  2. Grünwald V, Powles T,. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front Oncol. 2023 Aug 16;13:1223282. doi:10.3389/fonc.2023.1223282. PMID: 37664025; PMCID: PMC10471185
  3. Motzer J, et al. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol. 2024;42:1222-1228. Supplementary. DOI https://doi.org/10.1200/JCO.23.01569
  4. Protocol for: Motzer R, Alekseev B, Rha S-Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384:1289- 300. DOI: 10.1056/NEJMoa2035716

References:

  1. J. Motzer et. al, 2024 Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study; June 2024 https://doi.org/10.1200/JCO.23.01569
  2. Grünwald V, Powles T,. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front Oncol. 2023 Aug 16;13:1223282. doi:10.3389/fonc.2023.1223282. PMID: 37664025; PMCID: PMC10471185
  3. Motzer J, et al. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol. 2024;42:1222-1228. Supplementary. DOI https://doi.org/10.1200/JCO.23.01569
  4. Protocol for: Motzer R, Alekseev B, Rha S-Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384:1289- 300. DOI: 10.1056/NEJMoa2035716

References:

  1. J. Motzer et. al, 2024 Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study; June 2024 https://doi.org/10.1200/JCO.23.01569
  2. Grünwald V, Powles T,. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front Oncol. 2023 Aug 16;13:1223282. doi:10.3389/fonc.2023.1223282. PMID: 37664025; PMCID: PMC10471185.
  3. Motzer J, et al. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol. 2024;42:1222-1228. Supplementary. DOI https://doi.org/10.1200/JCO.23.01569
  4. Protocol for: Motzer R, Alekseev B, Rha S-Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384:1289- 300. DOI: 10.1056/NEJMoa2035716.

References:

  1. J. Motzer et. al, 2024 Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study; June 2024 https://doi.org/10.1200/JCO.23.01569
  2. Grünwald V, Powles T,. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front Oncol. 2023 Aug 16;13:1223282. doi:10.3389/fonc.2023.1223282. PMID: 37664025; PMCID: PMC10471185.
  3. Motzer J, et al. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol. 2024;42:1222-1228. Supplementary. DOI https://doi.org/10.1200/JCO.23.01569
  4. Protocol for: Motzer R, Alekseev B, Rha S-Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384:1289- 300. DOI: 10.1056/NEJMoa2035716.

References

  1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer Version 2.2025 — September 6,2024.© National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. available at : https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. last access date :1/12/2024

References

  1. Motzer et. al, 2024 Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study; June 2024 https://doi.org/10.1200/JCO.23.01569
  2. Motzer J, et al. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol. 2024;42:1222-1228. Supplementary. DOI https://doi.org/10.1200/JCO.23.01569

SA-RCC-00041 | Exp 30 Oct 2026